Janssen R&D (Ireland) has described respiratory syncytial virus (RSV) inhibiting spiro-bearing derivatives reported to be potentially useful for the treatment of RSV infections.
Research at Nextgen Bioscience Co. Ltd. has led to the identification of ectonucleotide pyrophosphatase/phosphodiesterase family member 2 (ENPP2; autotaxin) inhibitors.
A recent Hanmi Holdings Co. Ltd. patent describes 1-phosphatidylinositol 3-phosphate 5-kinase (PIKfyve) inhibitors reported to be useful for the treatment of amyotrophic lateral sclerosis, rheumatoid arthritis and Crohn’s disease.
Tumor-associated calcium signal transducer 2 (TROP2), a clinically validated target in oncology, is a glycoprotein overexpressed in several solid tumors such as breast, lung, pancreatic, ovarian and prostate cancer. TROP2 antibody-drug conjugates (ADCs) have shown significant efficacy in a large number of cancer types but still are linked to substantial safety issues.
Researchers at 1200 Pharma LLC have undertaken preclinical analysis of KRAS G12C inhibitors in clinical phases with the aim of finding an explanation for the differences observed in therapeutic efficacy in tumor sites other than lung, including lung-derived metastases. Results pointed to potency and pharmacokinetics as key drivers of efficacy.
Carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) is an inhibitory factor on natural killer (NK) and T cells and is expressed in several cancer types and immune cells such as macrophages and neutrophils. Researchers from Suzhou Neologics Bioscience Co. Ltd. have investigated CEACAM1 as a potential target for cancer immunotherapy.
Researchers from Novartis AG recently reported on the preclinical activity of IAG-933, a first-in-class YAP1/TAZ pan-TEAD protein-protein interaction...
RSS
